Key Takeaways:
The FDA granted Fast Track designation to Liquidia Corporation's (LQDA) Yutrepia, an inhaled dry-powder treprostinil, for Raynaud's phenomenon associated with systemic sclerosis, opening a third potential indication for a drug that generated roughly $300.3 million in its first half-year on the market.
The designation covers a condition that affects up to 90% of systemic sclerosis patients, a rare autoimmune disease with the highest mortality rate among systemic rheumatic diseases. Raynaud's phenomenon causes recurrent episodes of pain, numbness and color changes in the fingers and toes, and can progress to digital ulcers and, in severe cases, amputation.
"Fast Track designation gives us a defined regulatory channel for a complication that currently has no approved therapy," a Liquidia spokesperson said, adding that the company expects to begin enrolling patients in October 2026.
Liquidia plans to start RE-WARM, a phase 2a randomized, open-label, dose-finding study of approximately 75 adults with SSc experiencing symptomatic Raynaud's attacks. The trial will run at up to 30 U.S. sites and assess safety and pharmacodynamics alongside the drug's ability to reduce the frequency, severity and impact of attacks. Primary completion is targeted for February 2027.
Fast Track status brings more frequent FDA interactions during development, eligibility for rolling review of a new drug application, and, if applicable criteria are met, potential priority review or accelerated approval. None of those benefits guarantee approval, and the designation does not shorten the clinical work RE-WARM must complete.
Yutrepia was approved in May 2025 for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, and launched commercially in June 2025. Liquidia has recorded about 5,900 unique prescriptions and more than 5,000 patients initiated on the therapy since launch. The company is separately evaluating the drug in pulmonary hypertension associated with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
The competitive picture is crowded. United Therapeutics (UTHR) markets Tyvaso, an inhaled treprostinil approved for PAH in 2009 and PH-ILD in 2021, plus Tyvaso DPI, a dry-powder formulation cleared for both indications in 2022. UTHR is advancing ralinepag tablets for PAH and nebulized Tyvaso for IPF, with planned filings for ralinepag DPI and treprostinil SMI. Insmed (INSM) is enrolling the phase 3 PALM-ILD and PALM-PAH trials of TPIP, an inhaled dry-powder treprostinil prodrug, and plans a phase 3 study in progressive pulmonary fibrosis in the second half of 2026 followed by IPF in the first half of 2027.
Liquidia's PRINT technology, which delivers the drug deeper into the lungs through an easy-to-use inhaler while enabling higher doses than other inhaled treprostinil therapies, is the basis for the company's differentiation claim. Whether that translates into a Raynaud's benefit is what RE-WARM is designed to test.
Shares of LQDA have climbed 100.4% year to date, against 7.4% growth for the industry. The stock trades at 6.22 times forward sales, above the industry average of 1.89 times but below its own mean of 14.68 times. The Zacks Consensus Estimate for 2026 earnings per share has fallen to $2.57 from $3.02 over the past 60 days, and the 2027 estimate has slipped to $4.38 from $4.92. LQDA carries a Zacks Rank #4 (Sell).
For holders, the Fast Track designation is a pipeline signal rather than a revenue event: it costs nothing and commits nothing, but it puts a rare-disease indication with no approved therapy on a faster review track. The next hard data point is RE-WARM enrollment beginning in October 2026, with primary completion targeted for February 2027. Until then, Yutrepia's growth story rests on the PAH and PH-ILD labels and the roughly $300.3 million first-half run rate those two indications produced.
This article is for informational purposes only and does not constitute investment advice.
